Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)
China · Delayed Price · Currency is CNY 41.86
-0.32 (-0.76%)
At close: Feb 6, 2026
SHA:603392 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,765 | 2,215 | 5,493 | 11,167 | 5,702 | 2,337 |
Other Revenue | 30.31 | 30.31 | 17.3 | 18.52 | 48.34 | 17.14 |
| 1,796 | 2,245 | 5,511 | 11,185 | 5,750 | 2,354 | |
Revenue Growth (YoY) | -27.88% | -59.25% | -50.73% | 94.51% | 144.25% | 98.88% |
Cost of Revenue | 937.13 | 866.34 | 1,084 | 1,198 | 850.67 | 473.6 |
Gross Profit | 858.53 | 1,379 | 4,427 | 9,987 | 4,900 | 1,881 |
Selling, General & Admin | 821.68 | 790.16 | 1,878 | 3,490 | 1,874 | 810.21 |
Research & Development | 593.87 | 874.57 | 1,177 | 1,091 | 677.42 | 309.13 |
Other Operating Expenses | 112.49 | 14.67 | 31.57 | 51.28 | 26.71 | 12.51 |
Operating Expenses | 1,568 | 1,694 | 3,063 | 4,723 | 2,662 | 1,156 |
Operating Income | -709.07 | -315.37 | 1,364 | 5,265 | 2,238 | 724.74 |
Interest Expense | -9.11 | -8.32 | -6.86 | -7.67 | -5.69 | -1.69 |
Interest & Investment Income | 109.75 | 169.09 | 186.88 | 78.26 | 21 | 18.58 |
Currency Exchange Gain (Loss) | 7.42 | 7.42 | 13.01 | 27.89 | -8.75 | -14.29 |
Other Non Operating Income (Expenses) | 15.26 | -5.77 | -1.87 | -1 | 0.05 | -0.79 |
EBT Excluding Unusual Items | -585.74 | -152.95 | 1,555 | 5,362 | 2,244 | 726.55 |
Gain (Loss) on Sale of Investments | 46.45 | 36.71 | 24.66 | 9.98 | 0.03 | 0.35 |
Gain (Loss) on Sale of Assets | 5.36 | 7.39 | -1.08 | -2.74 | -0.97 | 0.42 |
Asset Writedown | -6.31 | - | -259.15 | - | - | - |
Other Unusual Items | 169.72 | 176.33 | 73.7 | 213.42 | 80.85 | 37.13 |
Pretax Income | -370.53 | 67.48 | 1,393 | 5,583 | 2,324 | 764.45 |
Income Tax Expense | -35.24 | -41.61 | 146.89 | 719.39 | 244.93 | 82.64 |
Earnings From Continuing Operations | -335.28 | 109.09 | 1,247 | 4,863 | 2,079 | 681.82 |
Minority Interest in Earnings | 1.45 | -2.86 | 1.18 | -127.51 | -57.75 | -4.82 |
Net Income | -333.84 | 106.24 | 1,248 | 4,736 | 2,021 | 677 |
Net Income to Common | -333.84 | 106.24 | 1,248 | 4,736 | 2,021 | 677 |
Net Income Growth | - | -91.48% | -73.65% | 134.28% | 198.59% | 224.13% |
Shares Outstanding (Basic) | 1,305 | 1,328 | 1,260 | 1,250 | 1,230 | 1,195 |
Shares Outstanding (Diluted) | 1,305 | 1,328 | 1,260 | 1,250 | 1,230 | 1,195 |
Shares Change (YoY) | 3.21% | 5.37% | 0.86% | 1.55% | 2.96% | 8.71% |
EPS (Basic) | -0.26 | 0.08 | 0.99 | 3.79 | 1.64 | 0.57 |
EPS (Diluted) | -0.26 | 0.08 | 0.99 | 3.79 | 1.64 | 0.57 |
EPS Growth | - | -91.92% | -73.88% | 130.69% | 190.01% | 198.16% |
Free Cash Flow | -575.35 | -532.27 | 378.15 | 3,203 | 634.16 | 77.77 |
Free Cash Flow Per Share | -0.44 | -0.40 | 0.30 | 2.56 | 0.52 | 0.07 |
Dividend Per Share | - | - | 0.320 | 0.714 | 0.099 | 0.088 |
Dividend Growth | - | - | -55.20% | 624.44% | 12.04% | - |
Gross Margin | 47.81% | 61.42% | 80.34% | 89.29% | 85.21% | 79.88% |
Operating Margin | -39.49% | -14.04% | 24.75% | 47.07% | 38.91% | 30.78% |
Profit Margin | -18.59% | 4.73% | 22.64% | 42.34% | 35.15% | 28.76% |
Free Cash Flow Margin | -32.04% | -23.71% | 6.86% | 28.63% | 11.03% | 3.30% |
EBITDA | -432.49 | -65.06 | 1,579 | 5,401 | 2,334 | 809.21 |
EBITDA Margin | -24.09% | -2.90% | 28.66% | 48.28% | 40.59% | 34.37% |
D&A For EBITDA | 276.58 | 250.31 | 215.29 | 136.17 | 96.2 | 84.47 |
EBIT | -709.07 | -315.37 | 1,364 | 5,265 | 2,238 | 724.74 |
EBIT Margin | -39.49% | -14.04% | 24.75% | 47.07% | 38.91% | 30.78% |
Effective Tax Rate | - | - | 10.54% | 12.89% | 10.54% | 10.81% |
Revenue as Reported | 1,796 | 2,245 | 5,511 | 11,185 | 5,750 | 2,354 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.